2. Search Result
Search Result
Results for "

intake

" in MedChemExpress (MCE) Product Catalog:

253

Inhibitors & Agonists

3

Screening Libraries

5

Biochemical Assay Reagents

84

Peptides

1

Inhibitory Antibodies

26

Natural
Products

10

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3462
    Cagrilintide
    3 Publications Verification

    		 CGRP Receptor Metabolic Disease
    Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
    Cagrilintide
  • HY-P3462A
    Cagrilintide acetate
    3 Publications Verification

    		 CGRP Receptor Metabolic Disease
    Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
    Cagrilintide acetate
  • HY-P4146
    Survodutide

    BI 456906

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide
  • HY-P3463
    Beinaglutide
    1 Publications Verification

    GLP-1 (human)

    		 GCGR Metabolic Disease Inflammation/Immunology
    Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .
    Beinaglutide
  • HY-160734
    Aleniglipron

    GSBR-1290

    		 GLP Receptor Metabolic Disease
    Aleniglipron (GSBR-1290) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist, with an EC50 value of less than 0.1 nM in HDB cell lines in cAMP stimulation assays. Aleniglipron selectively activates the Gαs-cAMP signaling pathway of GLP-1R without β-arrestin recruitment. Aleniglipron induces insulin release, promotes glucose clearance, reduces food intake and decreases body weight. Aleniglipron is applicable to research related to type 2 diabetes and obesity .
    Aleniglipron
  • HY-10895
    SB-334867
    5+ Cited Publications

    SB 334867A

    		 Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    SB-334867 (SB 334867A) is an excellent,selective and blood-brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pKb=7.4), 100-fold over 5-HT2B, 5-HT2C with pKi values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .
    SB-334867
  • HY-W010042
    L-Glucose
    1 Publications Verification

    L-(-)-Glucose

    		 Fluorescent Dye Metabolic Disease Cancer
    L-Glucose (L-(-)-Glucose) is a stereoisomer of D-Glucose (HY-B0389), which does not readily enter the brain. L-Glucose can promote food intake. L-glucose is combined with a fluorescence detector to produce a fluorescent probe that can be used to visualize and characterize cancer cells. L-Glucose also can be used in the research to enhance memory in mice .
    L-Glucose
  • HY-138795
    Curcumin-β-D-glucuronide

    		Endogenous Metabolite Cancer
    Curcumin-β-D-glucuronide is a major metabolite after oral intake of Curcumin in hepatic tissue and portal blood. Curcumin-β-D-glucuronide can be used for the research of colon cancer .
    Curcumin-β-D-glucuronide
  • HY-W017006
    1-Methyl-L-histidine
    2 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    1-Methyl-L-histidine is an objective indicator of meat ingestion and exogenous 3-methylhistidine (3MH) intake.
    1-Methyl-L-histidine
  • HY-116797
    MS15203

    MS0015203

    		 GPR171 Metabolic Disease
    MS15203 is a potent and selective GPR171 agonist. MS15203 increases food intake and body weight. MS15203 increases neuronal activity. MS15203 significantly increases the abundance of the mRNAs encoding proSAAS, NPY, AgRP .
    MS15203
  • HY-10895A
    SB-334867 free base
    5+ Cited Publications

    SB334867A free base

    		 Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    SB-334867 free base (SB334867A free base) is an excellent, selective and blood–brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pKb=7.4), 100-fold over 5-HT2B, 5-HT2C with pKi values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .
    SB-334867 free base
  • HY-101302
    Naltriben mesylate
    2 Publications Verification

    		 Opioid Receptor TRP Channel Inflammation/Immunology
    Naltriben mesylate is a potent δ2-opioid receptor antagonist and a TRPM7 activator. Naltriben mesylate shows Ki values of 0.013 nM, 19 nM and 152 nM for δ, μ and κ receptors, respectively. Naltriben mesylate enhances glioblastoma cell migration and invasion. Naltriben mesylate can be used in research into neurological diseases and cancer .
    Naltriben mesylate
  • HY-14342
    MK-5046
    2 Publications Verification

    		 Bombesin Receptor Metabolic Disease
    MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC50 and an EC50 value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .
    MK-5046
  • HY-W002116
    Methyl syringate

    		TRP Channel COX Phosphatase Bacterial Infection Metabolic Disease Inflammation/Immunology Cancer
    Methyl syringate is a selective TRPA1 agonist. Methyl syringate regulates food intake and gastric emptying through a TRPA1-mediated pathway. Methyl syringate is an efficient phenolic mediator for bacterial and fungal laccases. Methyl syringate is a chemical marker of Asphodel monofloral honey. Methyl syringate contributes to the antibacterial activity of honey. Methyl syringate inhibits aflatoxin production. Methyl syringate can contribute to weight suppression. Methyl syringate can be studies for cancer prevention (e.g. lung cancer), suppression of hypoxia-induced inflammatory response and tumorigenesis .
    Methyl syringate
  • HY-W041019
    5-Hydroxytryptophol
    1 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    5-Hydroxytryptophol is a mammalian serotonin metabolite that can be used as a sensitive biomarker for recent alcohol intake. 5-Hydroxytryptophol is formed by alcohol-induced changes in the serotonin metabolic pathway and is excreted in the urine as a glucuronic acid conjugate. 5-Hydroxytryptophol is elevated in urine excretion and can be used clinically to monitor alcohol intake in scenarios such as alcohol relapse .
    5-Hydroxytryptophol
  • HY-118930A
    MK-0493 hydrochloride

    		Melanocortin Receptor Metabolic Disease Endocrinology
    MK-0493 hydrochloride is a potent, orally active and selective agonist of the melanocortin receptor 4 (MC4R), demonstrating significant reductions in energy intake .
    MK-0493 hydrochloride
  • HY-P3704
    Enterostatin (rat)

    		Endogenous Metabolite Metabolic Disease
    Enterostatin (rat), an orally active activation peptide of procolipase, selectively reduces fat intake. Enterostatin (rat) reduces serum cholesterol levels by way of a CCK1 receptor-dependent mechanism .
    Enterostatin (rat)
  • HY-P2210
    BigLEN(mouse)

    		GPR171 Metabolic Disease
    BigLEN(mouse) is a potent and selective agonist of orphan G protein-coupled receptor 171 (GPR171), with a Kd of ∼0.5 nM. BigLEN(mouse) can be used to regulate responses associated with food intake and metabolism .
    BigLEN(mouse)
  • HY-P2932
    Cholecystokinin
    1 Publications Verification

    Cholecystokinin-33(human); CCK-33(human)

    		 Cholecystokinin Receptor Metabolic Disease
    Cholecystokinin is a peptide hormone. Cholecystokinin, as a hunger suppressant, inhibits food intake and stimulates the digestion of fat and protein. Cholecystokinin can be used for the research of gastrointestinal system .
    Cholecystokinin
  • HY-P3561A
    Agouti-related Protein (AGRP) (83-132) Amide (human) TFA

    		Melanocortin Receptor Neurological Disease
    Agouti-related Protein (AGRP) (83-132) Amide (human) TFA is a fragment of agouti-related protein (AGRP) which is a protein found in abundance in the arcuate nucleus of the hypothalamus. AgRP primarily acts as an inverse agonist for the melanocortin-4 receptor (MC4R) to increase food intake .
    Agouti-related Protein (AGRP) (83-132) Amide (human) TFA
  • HY-W015876
    L-Leucinol

    (+)-Leucinol

    		 Aminopeptidase Others
    L-Leucinol ((+)-Leucinol) is a competitive aminopeptidase inhibitor with a Ki value of 17 μM. As a dietary intake inhibitor, L-Leucinol reduces the basal dietary leucine intake in rats via microinjection into the rat anterior piriform cortex .
    L-Leucinol
  • HY-110206
    AM6545

    		Cannabinoid Receptor Metabolic Disease
    AM6545 is a highly selective, brain-free (peripherally active) CB1 receptor antagonist (Ki=1.7 nM). AM6545 inhibits endocannabinoid signaling by competitively antagonizing CB1 receptors, inhibiting CB1-mediated appetite stimulation and inflammatory responses without affecting cAMP levels. AM6545 significantly reduces food intake and body weight in mice, while improving metabolic syndrome-related renal impairment (such as proteinuria, fibrosis) and insulin resistance. AM6545 can be used in the study of obesity and its complications .
    AM6545
  • HY-P1215A
    HS024 TFA
    1 Publications Verification

    		 Melanocortin Receptor Metabolic Disease
    HS024 is a selective MC4 receptor antagonist, with Kis of 0.29, 3.29, 5.45, 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .
    HS024 TFA
  • HY-W010042S
    L-Glucose-13C
    1 Publications Verification

    L-(-)-Glucose-13C

    		 Isotope-Labeled Compounds Metabolic Disease
    L-Glucose- 13C is the 13C labeled L-Glucose. L-Glucose (L-(-)-Glucose) is an enantiomer of D-glucose. L-Glucose can promote food intake .
    L-Glucose-13C
  • HY-124821
    VA012

    		5-HT Receptor Neurological Disease Metabolic Disease
    VA012 (compound 11) is a positive allosteric modulator (PAM) of the serotonin 5-HT2C receptor. VA012 reduces food intake and body weight gain without causing CNS-related malaise during subchronic administration. VA012 can be utilized in obesity research .
    VA012
  • HY-P1322
    [D-Trp34]-Neuropeptide Y

    		Neuropeptide Y Receptor Neurological Disease
    [D-Trp34]-Neuropeptide Y is a potent and selective neuropeptide Y (NPY) Y5 receptor agonist. [D-Trp34]-Neuropeptide Y is a significantly less potent agonist at the NPY Y1, Y2, Y4, and y6 receptors. [D-Trp34]-Neuropeptide Y markedly increases food intake in rats .
    [D-Trp34]-Neuropeptide Y
  • HY-P1349A
    Orexin B, rat, mouse TFA
    1 Publications Verification

    Rat orexin B TFA; Orexin B (mouse) TFA

    		 Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    Orexin B, rat, mouse (Rat orexin B) TFA is an endogenous orexin receptor agonist. Orexin B, rat, mouse TFA binds and activates two closely related orphan G protein-coupled receptors OX1-R and OX2-R. Orexin B, rat, mouse TFA stimulates food intake and energy expenditure and plays a significant role in sleep-wakefulness regulation .
    Orexin B, rat, mouse TFA
  • HY-P1323A
    [Leu31,Pro34]-Neuropeptide Y(human,rat,mouse) TFA
    2 Publications Verification

    		 Neuropeptide Y Receptor Cardiovascular Disease Neurological Disease
    [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA is a specific neuropeptide Y Y1 receptor agonist. [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA slao activates Y4, Y5. [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA can increase blood pressure in anesthetized rats and increases food intake .
    [Leu31,Pro34]-Neuropeptide Y(human,rat,mouse) TFA
  • HY-101764
    Lintitript

    SR 27897

    		 Cholecystokinin Receptor Metabolic Disease
    Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC50 of 6 nM and a Ki of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for CCK1 than CCK2 receptors (EC50 value of 200 nM). Lintitript increases plasma concentration of leptin and food intake as well as plasma concentration of insulin .
    Lintitript
  • HY-163996
    DD202-114

    		GLP Receptor Potassium Channel Cytochrome P450 Metabolic Disease
    DD202-114 is a potent and selective GLP1R agonist. DD202-114 inhibits hERG with an IC50 of 15.9 μM. DD202-114 exhibits strong CYP2C8 inhibition with an IC50 of 0.22 μM. DD202-114 promotes cAMP accumulation. DD202-114 reduces blood glucose levels and food intake. DD202-114 has the potential to be used in the study of type 2 diabetes mellitus (T2DM) and obesity .
    DD202-114
  • HY-P11320
    Davalintide

    		Amylin Receptor CGRP Receptor Metabolic Disease
    Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC50 = 0.04 nM), calcitonin receptor (IC50 = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC50 = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC50 = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes .
    Davalintide
  • HY-P11291A
    NNC0165-1273 TFA

    		Neuropeptide Y Receptor Metabolic Disease
    NNC0165-1273 (TFA) is the trifluoroacetic acid of NNC0165-1273 (HY-P11291). NNC0165-1273 is an analog of gut hormone peptide YY (PYY3-36). NNC0165-1273 has a superior affinity for Y2 receptor over Y1, Y4, and Y5 receptor. NNC0165-1273 has a potent anorectic effect and significantly reduces nighttime and ghrelin-induced food intake by producing early satiety. NNC0165-1273 inhibits ghrelin-induced cFos expression in NPY/AgRP neurons. NNC0165-1273 can be used for antiobesity therapies research .
    NNC0165-1273 TFA
  • HY-P0259
    Xenin

    		Endogenous Metabolite Neurological Disease Metabolic Disease
    Xenin is a 25-amino acid peptide initially isolated from human gastric mucosa. Xenin is a gut hormone that can reduce food intake.
    Xenin
  • HY-N9483
    7-Keto-DHEA

    7-Oxo-DHEA; 7-Ketodehydroepiandrosterone; 7-Oxodehydroepiandrosterone

    		 GABA Receptor Metabolic Disease
    7-Keto-DHEA binds to GABA Receptor, and reduces the ethanol intake in rats. 7-Keto-DHEA exhibits potential in investigation of alcohol dependence disorders .
    7-Keto-DHEA
  • HY-W010042S3
    L-Glucose-13C6

    L-(-)-Glucose-13C6

    		 Isotope-Labeled Compounds Metabolic Disease
    L-Glucose- 13C6 (L-(-)-Glucose- 13C6) is C13-labeled L-Glucose. L-Glucose is an enantiomer of D-glucose. L-Glucose enhances food intake .
    L-Glucose-13C6
  • HY-W017006S
    1-Methyl-L-histidine-d3

    		Endogenous Metabolite Metabolic Disease
    1-Methyl-L-histidine-d3 is the deuterium labeled 1-Methyl-L-histidine. 1-Methyl-L-histidine is an objective indicator of meat ingestion and exogenous 3-methylhistidine (3MH) intake.
    1-Methyl-L-histidine-d3
  • HY-P1215
    HS024

    		Melanocortin Receptor Metabolic Disease
    HS024 is a selective MC4 receptor antagonist, with Kis of 0.29, 3.29, 5.45, and 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .
    HS024
  • HY-P1323
    [Leu31,Pro34]-Neuropeptide Y (human,rat)

    		Neuropeptide Y Receptor Cardiovascular Disease Neurological Disease
    [Leu31,Pro34]-Neuropeptide Y(human,rat) is a specific neuropeptide Y Y1 receptor agonist. [Leu31,Pro34]-Neuropeptide Y(human,rat) slao activates Y4, Y5. [Leu31,Pro34]-Neuropeptide Y(human,rat) can increase blood pressure in anesthetized rats and increases food intake .
    [Leu31,Pro34]-Neuropeptide Y (human,rat)
  • HY-101480
    Xylamidine

    		5-HT Receptor Neurological Disease
    Xylamidine is a peripheral 5-HT receptor antagonist used to investigate possible peripheral appetite suppressant effects of 5-hydroxytryptophan (5-HTP) and fenfluramine. In a 1-hour food intake test, xylamidine attenuated the decrease in food intake induced by 5-HT and 5-HTP, but had no effect on fenfluramine, suggesting that the appetite suppressant effect of 5-HTP is mediated in part through peripheral 5-HT receptors. Microstructural analysis revealed that 5-HTP and fenfluramine induced a decrease in food intake rate and a reduction in feeding batch size. Xylamidine reversed the effects of 5-HTP on food intake rate and induced a slight increase in feeding batch size itself, thus, the peripheral effect of 5-HTP appears to be to slow food intake rate. No effect of xylamidine on fenfluramine-induced changes in feeding was observed. The results suggest that the appetite suppressant effects of 5-HTP and fenfluramine are differentiated based on the peripheral effects of 5-HTP. The peripheral effects of 5-HTP are distinct from the previously reported 5-HT-induced decreases in feeding batch size and duration. Possible mechanisms underlying the differences in peripheral effects of 5-HT and 5-HTP are discussed.
    Xylamidine
  • HY-P3652
    Cholecystokinin-33 (swine)

    		Cholecystokinin Receptor Metabolic Disease
    Cholecystokinin-33 (swine) is a cholecystokinin (CCK) fragment. Cholecystokinin-33 (swine) can reduce food intake and gallbladder contraction .
    Cholecystokinin-33 (swine)
  • HY-P3561
    Agouti-related Protein (AGRP) (83-132) Amide (human)

    		Melanocortin Receptor Neurological Disease
    Agouti-related Protein (AGRP) (83-132) Amide (human) is a fragment of agouti-related protein (AGRP) which is a protein found in abundance in the arcuate nucleus of the hypothalamus. AgRP primarily acts as an inverse agonist for the melanocortin-4 receptor (MC4R) to increase food intake .
    Agouti-related Protein (AGRP) (83-132) Amide (human)
  • HY-P3130
    Stresscopin-related peptide (human)

    		CRFR Neurological Disease Inflammation/Immunology
    Stresscopin-related peptide (human) is a specific ligand for the type 2 CRH receptor. Stresscopin-related peptide (human) suppresses food intake, delayed gastric emptying and decreases heat-induced edema. Stresscopin-related peptide (human) maintains homeostasis after stress, and can be used in the research of stress-related diseases .
    Stresscopin-related peptide (human)
  • HY-P1216
    HS014

    		Melanocortin Receptor Neurological Disease
    HS014 is a potent and selective melanocortin-4 (MC4) receptor antagonist, with Kis of 3.16, 108, 54.4 and 694 nM for human MC4, MC1, MC3 and MC5 receptors, respectively. HS014 modulates the behavioral effects of morphine in mice. HS014 increases food intake in free-feeding rats .
    HS014
  • HY-19848
    Cevoglitazar

    LBM-642

    		 PPAR Metabolic Disease
    Cevoglitazar (LBM-642) is an orally active and highly potent PPARα and PPARγ dual agonist. Cevoglitazar can reduce food intake, body weight, and fasting plasma insulin in obese mice and cynomolgus monkeys. Cevoglitazar has the potential for diabetes and obesity-related disorders research .
    Cevoglitazar
  • HY-14342A
    (R)-MK-5046

    		Bombesin Receptor Metabolic Disease
    (R)-MK-5046 is the isomer of MK-5046 (HY-14342), and can be used as an experimental control. MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC50 and an EC50 value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .
    (R)-MK-5046
  • HY-P4146A
    Survodutide TFA

    BI 456906 TFA

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide TFA
  • HY-W002116S
    Methyl syringate-d6

    		TRP Channel COX Phosphatase Bacterial Infection Metabolic Disease Inflammation/Immunology Cancer
    Methyl syringate-d6 is the deuterium labeled Methyl syringate. Methyl syringate is a selective TRPA1 agonist. Methyl syringate regulates food intake and gastric emptying through a TRPA1-mediated pathway. Methyl syringate is an efficient phenolic mediator for bacterial and fungal laccases. Methyl syringate is a chemical marker of Asphodel monofloral honey. Methyl syringate contributes to the antibacterial activity of honey. Methyl syringate inhibits aflatoxin production. Methyl syringate can contribute to weight suppression. Methyl syringate can be studies for cancer prevention (e.g. lung cancer), suppression of hypoxia-induced inflammatory response and tumorigenesis .
    Methyl syringate-d6
  • HY-P1067
    Enterostatin(human,mouse,rat)

    		Endogenous Metabolite Metabolic Disease
    Enterostatin, human, mouse, rat is a pentapeptide that reduces fat intake.
    Enterostatin(human,mouse,rat)
  • HY-172744
    α-Hydroxy bromazolam

    		Drug Metabolite Metabolic Disease
    α-Hydroxy bromazolam is a metabolite of Bromazolam catalyzed by CYP enzymes and can be found in plasma and urine. α-Hydroxy bromazolam is an important biomarker for Bromazolam intake .
    α-Hydroxy bromazolam
  • HY-121827
    LH21
    1 Publications Verification

    		 Cannabinoid Receptor Metabolic Disease
    LH-21 is a potent in vivo neutral cannabinoid CB1 receptor antagonist. LH-21 reduces food intake and body weight gain in obese Zucker rats. , and displays efficacy as a feeding inhibitor .
    LH21

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: